CHAPTER 2

Systematic review and metaanalysis on nonclassic cardiovascular biomarkers after hypertensive pregnancy disorders

Sanne Visser
Wietske Hermes
Johannes Ket
Rene Otten
Maria van Pampus
Arie Franx
Kitty Bloemenkamp
Ben Mol
Christanne de Groot

*American Journal of Obstetrics and Gynecology 2014*
ABSTRACT

Objective: The aim of this study was to investigate which nonclassic cardiovascular biomarkers are associated with persistent endothelial dysfunction after pregnancy in women with a history of hypertensive pregnancy disorders compared with women with uncomplicated pregnancies.

Study design: This was a systematic review and metaanalysis of observational studies. A search was performed in PubMed, Embase, Cochrane, and Cinahl including articles from inception to Feb. 27, 2013. Included were cohort studies and case-control studies. Cases were women with a history of hypertension in pregnancy, control subjects were women with a history of uncomplicated pregnancies. Of the 3136 found, 21 studies on 16 nonclassic cardiovascular biomarkers are described in this review; 12 studies on 5 biomarkers were included in the metaanalysis.

Results: Women with a history of hypertensive pregnancy disorders had a higher homocysteine level compared with women with a history of uncomplicated pregnancies (5 studies; pooled mean difference, 0.77 ng/mL; 95% confidence interval, 0.27e1.26; P < .01). For the other nonclassic cardiovascular biomarkers including markers in areas of inflammation, thrombosis, and angiogenesis, we found no significant differences.

Conclusion: This review and metaanalysis showed that women with a history of hypertensive pregnancy disorders have higher homocysteine levels compared to women with a history of uncomplicated pregnancies. These data suggest persistent endothelial alteration after pregnancies complicated by hypertensive disorders.
INTRODUCTION

Cardiovascular disease is the leading cause of death in women in the Western world [1]. Cardiovascular disease manifests itself different between men and women; diagnostic tools in women are less sensitive and specific. Therefore, it is of additional value to identify specific risk factors for cardiovascular disease in women [2-5]. For women, preeclampsia has been suggested as a specific risk factor for cardiovascular disease later in life [6,7].

Hypertensive disorders in pregnancy are hypothesized to act as a stress test for cardiovascular disease later in life [8]; women who fail this stress test by developing hypertensive pregnancy disorders have an increased cardiovascular risk, which will become apparent during pregnancy. Both disorders, hypertensive pregnancy disorders and cardiovascular disease later in life, share a common pathophysiologic pathway [9] of endothelial dysfunction.

Recently a review on classic cardiovascular biomarkers showed higher levels of glucose, insulin, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and microalbumin and lower levels of high-density lipoprotein cholesterol in women with a history of hypertensive pregnancy disorders compared to women with a history of uncomplicated pregnancies [10]. These biochemical cardiovascular risk markers are predictors for cardiovascular disease later in life and might identify high-risk young women early enough to benefit from screening and intervention.

In addition to classic cardiovascular biomarkers, there is a wide variety of nonclassic cardiovascular biomarkers associated with endothelial dysfunction. These latter mentioned biomarkers might be more associated with future risk of cardiovascular disease and therefore might give options for preventive interventions [11-13].

In this systematic review and metaanalysis, we focus on 16 nonclassic cardiovascular biomarkers associated with persistent endothelial dysfunction, including inflammation (intercellular adhesion molecule [ICAM], vascular cell adhesion molecule [VCAM], interleukin-6 [IL-6], interleukin-10 [IL-10], and E-selectin), thrombosis (homocysteine, Von Willebrand factor [VWF], fibrinogen, fibrinectin, endothelin, D-dimer, plasminogen activator inhibitor-1 [PAI-1], tissue plasminogen activator [tPA]), and angiogenesis (vascular endothelial growth factor [VEGF], soluble Fms-like tyrosine kinase-1 [sFLT-1], and tumor necrosis factor alpha ([TNF-a]).

Previous research suggests that these cardiovascular biomarkers could be useful in prediction, identification, and assessment of hypertensive pregnancy disorders, especially preeclampsia [14,15]. Because cardiovascular disease and hypertensive pregnancy disorders share a (partly) common pathophysiology, we used these biomarkers in our search for this systematic review and metaanalysis.

The aim of this study was to investigate whether nonclassic cardiovascular biomarkers are associated with persistent endothelial dysfunction after pregnancy in women with a history of hypertensive pregnancy disorders compared to women who have had uncomplicated pregnancies.
Chapter 2

MATERIALS AND METHODS

Definitions
Hypertensive pregnancy disorders include gestational hypertension, preeclampsia, superimposed preeclampsia, and eclampsia. Gestational hypertension was defined according to the International Society for the Study of Hypertension in Pregnancy criteria as diastolic blood pressure of 90 mmHg or greater measured on 2 occasions at least 6 hours apart in a woman who was normotensive at the start of pregnancy until week 20 of gestational age [16].

Preeclampsia was defined according to the International Society for the Study of Hypertension in Pregnancy criteria: onset of a blood pressure exceeding 140/90 mmHg with proteinuria greater than 0.3 g per 24 hours after 20 weeks’ gestation [16]. Severe preeclampsia was defined as a blood pressure exceeding 160/110 mmHg or proteinuria greater than 5 g per 24 hours, or both [16]. Eclampsia was defined as the presence of seizures [16,17]. Superimposed preeclampsia was defined as preexisting hypertension with new onset proteinuria greater than 0.3 g per 24 hours after 20 weeks’ gestation.

Sources
We searched PubMed, Embase.com, Cochrane Library (via Wiley), and Cinahl (via EBSCO) (J.C.F.K., R.H.J.O., and S.V.) from inception to Feb. 27, 2013. The following search terms with synonyms were used: gestational hypertension, preeclampsia, and eclampsia.

The search on nonclassic cardiovascular biomarkers in the area of inflammation included the following terms with synonyms: ICAM, VCAM, IL-6, IL-10, and E-selectin. The search on nonclassic cardiovascular biomarkers in the area of thrombosis included the following terms with synonyms: homocysteine, VWF, fibrinogen, fibronectin, endothelin, D-dimer, PAI-1, and tPA. The search on nonclassic cardiovascular biomarkers in the area of angiogenesis included the following terms with synonyms: VEGF, sFLT-1, and TNF-a. The search for study type included the following terms with synonyms: systematic reviews, metaanalyses, cohort studies and case-control studies. The choice of biochemical markers was based on the knowledge of their role in hypertensive disorders in pregnancy and suspected endothelial activation.

Study selection
We included case-control studies and cohort studies. Further inclusion criteria hold cases described in the articles had to be women with a history of hypertensive pregnancy disorder by previous mentioned definition, control subjects had to be women with a history of uncomplicated pregnancies, the articles should describe measurements in blood samples of 1 of the nonclassic cardiovascular biomarkers as described above, and blood sample should be drawn more than 6 weeks after delivery. There were no limitations made on publication date or patients sample size.

We excluded studies without the definitions of gestational hypertension or (pre)eclampsia or without baseline criteria of the study population mentioned above. Studies that included superimposed preeclampsia were excluded from this review.
Markers after Hypertensive Pregnancy Disorders

Two reviewers (S.V., W.H.) screened the title, abstract and key words (figure 1). All titles were screened by the 2 reviewers (S.V., W.H.). If the title was not specific enough for decision on inclusion or exclusion, we reviewed the abstract according to the following criteria: case control or cohort study and blood samples drawn after pregnancy complicated by hypertensive disorders. No exclusions were made on publication date or language of article. If a reference was potentially eligible, a full-text article was scored using a scoring list conducted by the reviewers (S.V.,W.H., C.J.M.d.G.) to assess the article’s quality.

Explicit definitions of gestational hypertension and (pre) eclampsia, parity, mean gestational age, preterm or term pregnancy, number of cases and controls included, follow-up time, and adequate information about blood collection and blood analysis (i.e. if blood samples were taken sober) were required for inclusion in this systematic review. During the comparison of these scoring lists by the reviewers (S.V., W.H.), any inconsistencies were resolved by discussion with a third reviewer (C.J.M.d.G.).

Outcomes of interest

Outcomes were differences in nonclassic cardiovascular biomarkers, measured after pregnancy, between women with a history of hypertensive pregnancy disorders and women with a history of uncomplicated pregnancies. Nonclassic cardiovascular biomarkers found in case-control and cohort studies were numerous (table 1).

Figure 1.
In this review we describe a specific selection of nonclassic cardiovascular biomarkers (n = 16), ICAM, VCAM, IL-6, IL-10, E-selectin, homocysteine, VWF, fibrinogen, fibronectin, endothelin, D-dimer, PAI-1, tPA, VEGF, sFLT-1, and TNF-a. Only if 3 or more studies reported on a nonclassic biomarker and reported outcome values as means ± SEM or SD, we performed a metaanalysis including the nonclassic biomarker. If studies reported values as medians (range/interquartile range) or if less than 3 studies reported on the nonclassic biomarker, we described the nonclassic biomarker separately.

**Data synthesis**

We used Review Manager 5.0 (Cochrane Collaboration, Oxford, UK) for statistical analyses. Outcomes were reported as continuous data and analyzed using a mean difference. Raw numbers were used from each study, as adjustments for confounding effects varied among the different studies. Weighting of studies in the metaanalyses was calculated on the basis of the inverse variance of the study. The random effects model was chosen because a clinical and statistical heterogeneity was expected among the studies. We used forest plots to visualize data and assessed heterogeneity using the I2 test [18]. For all effect estimates, a value of P < .05 indicated statistical significance.

**RESULTS**

**Literature identification and study quality**

The initial search produced 4995 articles: PubMed 1775 articles, Embase 2757 articles, Cinahl 260 articles, and Cochrane 119 articles. After removing duplicates of references that were selected from more than 1 database, 3136 articles remained. After screening the titles and abstracts, we retrieved 73 articles for detailed evaluation of the full text. As described in the figure 1, we included 21 articles of these 73 in this review. For the metaanalyses we included 12 articles that reported on 5 different nonclassic cardiovascular biomarkers. The other nonclassic cardiovascular biomarkers will be described separately.

**Study characteristics**

The studies included in this review were published from 1994 to 2012. Study characteristics are shown in the table 1. Data collection of studies in this review was prospective design in 15 studies (71%) [20-23,25,27-29,32-37,39]. Six studies (29%) were designed as cohort studies [19,25,26,30,31,38] and 15 (71%) were case control studies [20-24,27-29,32-37,39].

In 1 study (5%), only women with a history of pregnancy induced hypertension were included [30]; 2 studies (9%) included women with a history of pregnancy induced hypertension and preeclampsia [25,31], and 18 studies (86%) included women with a history of preeclampsia [19-24,27-30,32-39].

In 11 studies (52%), both nulliparous and multiparous women were included [19,20,22-24,28,30,31,34,37,39]; in 7 other studies (32%), only nulliparous women were included [25-27,29,32,33,36]. We included 3 studies (14%) in which parity was not described [21,35,38]. In 3
Markers after Hypertensive Pregnancy Disorders

25

studies (14%), women were included only after a term pregnancy [19,30,31]; in 7 studies (33%), women who delivered at both term and at preterm were included [20,25,33-36,39]. In the other 11 studies (52%), it was not reported whether women delivered at term or preterm [21-24,26-29,32,37,38]. The follow-up period of the included studies varied from 5 months to 52 years. An overall mean weighted follow-up was not calculated because the follow-up periods in the different studies were reported as means (±SD) or medians (ranges/interquartile range).

Biomarkers for inflammation
ICAM and VCAM [24,25,27,32,33,36].

Five studies with a total of 534 cases and 264 controls were able to be included in metaanalyses on ICAM [24,27,32,33,36], which showed no significant difference in mean ICAM levels in women with a history of hypertensive pregnancy disorders compared with women with a history of uncomplicated pregnancy (mean difference, 11.04 ng/mL; 95% confidence interval [CI], -12.10 to 34.18; P = 0.35). The test heterogeneity observed was significant (P = 0.04, I² = 61%) (figure A). One study described a higher median ICAM level [25] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy.

Three studies with a total of 116 cases and 106 controls were able to be included in metaanalyses on VCAM, which showed no significant difference in mean VCAM levels in women with a history of hypertensive pregnancy disorders compared with women with a history of uncomplicated pregnancy (mean difference, 68.72 ng/mL; 95% CI, -150.86 to -288.29). The test heterogeneity observed was significant (P<0.00, I² = 97%) (figure B). One study described a higher median VCAM level [25] in women with a history of hypertensive pregnancy disorders compared to women with an uncomplicated pregnancy.

Two studies described higher mean IL-6 levels [27,33], and 1 study described a higher median IL-6 level [31] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy. One study described a lower median IL-6 level [34] in women with a history of hypertensive pregnancy disorders compared to women with a history of uncomplicated pregnancy. Overall, IL-6 levels were described higher after pregnancy in women with a history of hypertensive pregnancy disorders compared to women with a history of uncomplicated pregnancy.

One study described a higher mean IL-10 level [27] in women with a history of hypertensive pregnancy disorders compared with women with uncomplicated pregnancy.

One study described a higher mean E-selectin level [24] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy. One study described the same mean E-selectin level [32] in women with a history of hypertensive pregnancy disorders and women with uncomplicated pregnancy. Two studies described higher median E-selectin levels [25,39] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy. Overall, E-selectin levels were described higher after pregnancy in women with a history of hypertensive pregnancy disorders compared to women with a history of uncomplicated pregnancy.
Biomarkers for thrombosis

Homocysteine, VWF, and fibrinogen [19,20,23,24,26,28,30-35,37]

Five studies with a total of 390 cases and 342 controls could be included in metaanalyses on homocysteine [24,28,30,31,37], which showed higher mean homocysteine levels in women with a history of hypertensive pregnancy disorders compared to women with a history of uncomplicated pregnancy (mean difference, 0.77 ng/mL; 95% CI 0.27 to 1.26; P <0.00). The test heterogeneity observed was not significant (P =0.11, I² = 48%) (figure C).

Three studies with a total of 473 cases and 209 controls could be included in metaanalyses on VWF [19,26,32], which showed no significant difference in mean VWF levels in women with a history of hypertensive pregnancy disorders compared with women with a history of uncomplicated pregnancy (mean difference, 0.06 ng/mL; 95% CI -0.05 to 0.17; P = 0.28). The test heterogeneity observed was not significant (P = 0.47, I² = 0%) (figure D). Two studies described higher VWF median levels [23,34] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy.

Four studies with a total of 778 cases and 319 controls could be included in metaanalyses on fibrinogen [20,26,32,33] which showed no significant difference in mean fibrinogen levels in women with a history of hypertensive pregnancy disorders compared with women with a history of uncomplicated pregnancy (mean difference, 0.28 g/L; 95% CI -0.02 to 0.59; P = 0.07). The test heterogeneity observed was significant (P = 0.02, I² = 70%) (figure E).

Two studies described higher median fibrinogen levels [23,35] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy.

Two studies described higher mean cellular fibronectin levels [19,20] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy. One
Markers after Hypertensive Pregnancy Disorders

Figure C. Von Willebrand Factor (VWF)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Cases Mean [U/ml]</th>
<th>SD [U/ml]</th>
<th>Total</th>
<th>Controls Mean [U/ml]</th>
<th>SD [U/ml]</th>
<th>Total</th>
<th>Weight IV, Random, 95% CI [U/ml]</th>
<th>Mean Difference IV, Random, 95% CI [U/ml]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deng 1994</td>
<td>1.11</td>
<td>0.4</td>
<td>63</td>
<td>1</td>
<td>0.3</td>
<td>29</td>
<td>0.11 [-0.04, 0.26]</td>
<td></td>
</tr>
<tr>
<td>Hamad 2007</td>
<td>1.07</td>
<td>0.38</td>
<td>18</td>
<td>1.01</td>
<td>0.29</td>
<td>17</td>
<td>0.96 [-0.16, 0.28]</td>
<td></td>
</tr>
<tr>
<td>Vickers 2003</td>
<td>1.65</td>
<td>1.18</td>
<td>392</td>
<td>1.71</td>
<td>1.27</td>
<td>163</td>
<td>-0.05 [-0.29, 0.17]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>473</td>
<td></td>
<td></td>
<td>209</td>
<td>100.0%</td>
<td></td>
<td>0.06 [-0.05, 0.17]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.00; Chi² = 1.51, df = 2 (P = 0.47); I² = 0%
Test for overall effect: Z = 1.08 (P = 0.28)

Cases

Figure D. Homocysteine

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Cases Mean [µmol/L]</th>
<th>SD [µmol/L]</th>
<th>Total</th>
<th>Controls Mean [µmol/L]</th>
<th>SD [µmol/L]</th>
<th>Total</th>
<th>Weight IV, Random, 95% CI [µmol/L]</th>
<th>Mean Difference IV, Random, 95% CI [µmol/L]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chambers 2001</td>
<td>9</td>
<td>3</td>
<td>78</td>
<td>8</td>
<td>2</td>
<td>48</td>
<td>1.00 [0.13, 1.87]</td>
<td></td>
</tr>
<tr>
<td>Coffeng 2011</td>
<td>8.7</td>
<td>1.7</td>
<td>16</td>
<td>11</td>
<td>6</td>
<td>17</td>
<td>-2.30 [-5.27, 0.67]</td>
<td></td>
</tr>
<tr>
<td>Giroud 2007</td>
<td>8.9</td>
<td>2.5</td>
<td>168</td>
<td>8</td>
<td>1.8</td>
<td>168</td>
<td>0.90 [0.42, 1.37]</td>
<td></td>
</tr>
<tr>
<td>Paradis 2006</td>
<td>8.2</td>
<td>0.8</td>
<td>15</td>
<td>7.7</td>
<td>0.4</td>
<td>15</td>
<td>0.50 [0.05, 0.95]</td>
<td></td>
</tr>
<tr>
<td>Raijmakers 2004</td>
<td>13.1</td>
<td>5</td>
<td>113</td>
<td>11.5</td>
<td>4.8</td>
<td>94</td>
<td>1.00 [0.26, 2.94]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>390</td>
<td></td>
<td></td>
<td>342</td>
<td>100.0%</td>
<td></td>
<td>0.77 [0.29, 1.26]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.12; Chi² = 7.48, df = 4 (P = 0.11); I² = 47%
Test for overall effect: Z = 3.14 (P = 0.002)

Cases

study described a higher mean endothelin levels [21] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy. One study described the same mean endothelin level [22] in women with a history of hypertensive pregnancy disorders and women with uncomplicated pregnancy.

One study described a higher mean D-dimer level [20] and 1 study described a higher median D-dimer level [35] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy.

One study described a higher mean PAI-1 level [20] and three studies described higher median PAI-1 levels [23,31,32] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy. One study described a lower mean PAI-1 level [35] in women with a history of hypertensive pregnancy disorders compared with women with uncomplicated pregnancy.

One study described a higher mean tPA level [32] and 2 studies described higher median tPA levels [23,35] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy.

Figure E. Fibrinogen

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Cases Mean [g/L]</th>
<th>SD [g/L]</th>
<th>Total</th>
<th>Controls Mean [g/L]</th>
<th>SD [g/L]</th>
<th>Total</th>
<th>Weight IV, Random, 95% CI [g/L]</th>
<th>Mean Difference IV, Random, 95% CI [g/L]</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bremme 1996</td>
<td>3.64</td>
<td>1.15</td>
<td>28</td>
<td>2.9</td>
<td>0.55</td>
<td>26</td>
<td>0.74 [0.26, 1.22]</td>
<td></td>
</tr>
<tr>
<td>Hamad 2007</td>
<td>3.6</td>
<td>0.7</td>
<td>18</td>
<td>3.3</td>
<td>0.8</td>
<td>17</td>
<td>0.30 [-0.20, 0.80]</td>
<td></td>
</tr>
<tr>
<td>vRijn 2007</td>
<td>3.4</td>
<td>1.38</td>
<td>392</td>
<td>3.41</td>
<td>0.84</td>
<td>163</td>
<td>-0.01 [-0.20, 0.18]</td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>778</td>
<td></td>
<td></td>
<td>319</td>
<td>100.0%</td>
<td></td>
<td>0.28 [-0.02, 0.59]</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.06; Chi² = 10.07, df = 3 (P = 0.02); I² = 70%
Test for overall effect: Z = 1.82 (P = 0.07)
Biomarkers for angiogenesis

VEGF, sFLT-1, and TNF-a [27, 29, 31, 38, 39]

Two studies described higher median VEGF levels [29,39] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy.

One study described a higher mean sFlt level [29], and 1 study describes higher median sFlt level [39] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy.

One study described a higher mean TNF-a level [27], and 1 study described a higher median TNF-a level [38] in women with a history of hypertensive pregnancy disorders compared to women with uncomplicated pregnancy. One study described a lower median TNF-a level [31] in women with a history of hypertensive pregnancy disorders compared with women with uncomplicated pregnancy.

**COMMENT**

In this review and metaanalysis, we found that most nonclassic cardiovascular biomarkers were higher in women with a history of hypertensive pregnancy disorders compared to women with a history of uncomplicated pregnancies in the areas of inflammation, thrombosis, and angiogenesis. Homocysteine was the only biomarker that was significantly higher in women with a history of hypertensive pregnancy disorders compared with women with a history of uncomplicated pregnancies.

This is the first review and metaanalyses that focused on nonclassic cardiovascular biomarkers in women with a history of hypertensive pregnancy disorders. We used a wide spectrum of search terms to evaluate the most important nonclassic cardiovascular biomarkers. The study selection was carried out without language restrictions, and attention was paid to quality assessment by using scoring lists and evaluation by multiple investigators, preventing selection bias and publication bias.

This review and metaanalyses shows higher levels of nonclassic cardiovascular biomarkers in women with a history of hypertensive pregnancy disorders. These elevated biomarkers suggest endothelial activation in hypertensive pregnancy disorders and cardiovascular disease, inclining toward a shared pathophysiology. Our metaanalyses suggest an additional value of one specific biomarker, homocysteine, in the cardiovascular risk assessment.

Guidelines advise treatment in women with elevated cardiovascular risk scores and unfavorable classic cardiovascular risk factors, such as hypercholesterolemia or diabetes, to prevent cardiovascular disease later in life [40,41]. However, until now, no evidence exists that treatment of nonclassic cardiovascular risk factors is effective in the prevention of cardiovascular disease in women [41]. An example is the lack of evidence that, in the case of elevated homocysteine, folic acid supplementation can result in reduction of cardiovascular events [42].

This review has some limitations. First, because of the small number of studies, we were not able
Markers after Hypertensive Pregnancy Disorders

To separately analyze women with a history of gestational hypertension and women with a history of preeclampsia, which may have different pathophysiology [43]. Second, studies did not distinguish between severe and non-severe disease and between preterm and term hypertensive pregnancy disorders, which may also differ pathophysiologic [44]. Third, follow-up time after pregnancy differed between studies. Fourth, both premenopausal and postmenopausal subjects were included in the studies reviewed. Postmenopausal women have a higher cardiovascular disease risk compared to premenopausal women. Thus, post menopause may have confounded our results, although studies that describe only premenopausal women seem to show comparable elevated levels of nonclassical biomarkers in women with a history of hypertensive pregnancy disorders compared with women with a history of uncomplicated pregnancy remained.

For thrombotic biomarker homocysteine, we found a significantly higher level in our metaanalyses for women with a history of hypertensive pregnancy disorders compared to women with a history of uncomplicated pregnancies. Homocysteine is a biomarker that is linked to the development of atherosclerosis, inflammation, and endothelium injury [45,46]. A large review conducted in 2002 [47] concluded that an increase in fasting plasma homocysteine is associated with an increase in the incidence of ischemic heart disease and an increase in the incidence of stroke.

Homocysteine is a marker for not only cardiovascular disease but also for hypertensive pregnancy disorders [48]. A recent study included homocysteine in an early prediction model for preeclampsia [49]. This study concluded that higher levels of homocysteine, in combination with elevation of other biomarkers, in the first trimester of pregnancy could predict the onset of the hypertensive pregnancy disorders later in pregnancy.

In our review, we included homocysteine levels after hypertensive pregnancy disorders. In 2 studies on homocysteine, it is not completely clear whether the results included fasting homocysteine levels [28,31]. Because homocysteine levels can be influenced by oral intake, this could disturb the results of this metaanalyses. The higher levels of homocysteine after a pregnancy complicated by hypertension can result from already present endothelial alteration or persistent endothelial alteration after complicated pregnancy. However, the impact of this finding and clinical consequences are unknown. The effectiveness of lowering of homocysteine levels, by folate acid or vitamin supplementation, to prevent cardiovascular disease has been investigated in several studies [50]. However, a Cochrane Review published in 2013 [42], failed to show evidence to sustain this.

For inflammatory biomarkers ICAM and VCAM, we found no significant differences in levels in our metaanalyses in women with a history of hypertensive pregnancy disorders compared to women with a history of uncomplicated pregnancies. An increase in systemic inflammation can be interpreted as either a cause or a result of atherogenesis in cardiovascular disease or both. Systemic inflammation induces a heightened state of cardiovascular activity, endothelium dysfunction, and induction of adhesion molecules on endothelial cells to which recruited inflammatory cells adhere and translocate to the arterial wall. This inflammatory process results in macrophage activation with the production of cytokines and other inflammatory biomarkers. These inflammatory biomarkers include ICAM, VCAM, IL-6 and IL-10.

We expected higher levels of inflammatory biomarkers in women with a history of hypertensive
pregnancy disorders compared with women with a history of uncomplicated pregnancies because the inflammatory process is an important part of the pathophysiology of both hypertensive pregnancy disorders as of cardiovascular disease \([51,52]\). However, we found higher levels only for women with a history of hypertensive disorders in the included articles but not a significant difference in our metaanalyses. Limited sample size might account for this.

For thrombotic biomarkers fibrinogen and VWF, we found no significant differences in our meta-analyses in women with a history of hypertensive pregnancy disorders compared with women with a history of uncomplicated pregnancies. Biomarkers for thrombosis indicate over-activation of thrombotic reactions without any blood vessel injury and may result in reduced blood flow, reduced perfusion, and finally cardiovascular disease. In this review, we described established biomarkers for thrombosis in women with a history of hypertensive pregnancy disorders. Most of these biomarkers are known to be elevated in women with preeclampsia and are even used in the early prediction of preeclampsia \([52,53]\). It has been suggested that thrombosis might be a shared pathophysiological pathway, partly explaining the link between hypertensive pregnancy disorders and cardiovascular disease later life. However, we did not find strong evidence for this in our present review.

**Conclusion**

Women with a history of hypertensive pregnancy disorders show significantly higher levels of homocysteine compared to women with a history of uncomplicated pregnancy. For other biomarkers of inflammation, thrombosis and angiogenesis, we found no significant increases. These findings suggest impaired endothelial function that persists after or is even already present before hypertensive pregnancy disorders.
Table 1. Characteristics of Included Studies in Review and Meta-analysis

<table>
<thead>
<tr>
<th>Study, country</th>
<th>Study design</th>
<th>Exposure</th>
<th>Parity index pregnancy</th>
<th>Mean gestational age (weeks)</th>
<th>Preterm and/or term pregnancy</th>
<th>Cases no.</th>
<th>Controls no.</th>
<th>Follow up period (years)</th>
<th>Non-classic Cardiovascular Marker described</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Deng 1994*, Sweden</td>
<td>Prospective Cohort</td>
<td>PE</td>
<td>NP+MP</td>
<td>Not reported</td>
<td>T</td>
<td>63</td>
<td>29</td>
<td>1 (5-15months)</td>
<td>VWF, fibronectin (means)</td>
</tr>
<tr>
<td>2. Bremme 1996*, Sweden</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP+MP</td>
<td>Severe PE 33 Mild PE 35</td>
<td>PT+T</td>
<td>42</td>
<td>26</td>
<td>1 (6-15months)</td>
<td>Fibronectin, Fibrinogen, PAI-1, Ddimer (means)</td>
</tr>
<tr>
<td>3. Laivuori 1997, Finland</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>Not reported</td>
<td>Not reported</td>
<td>Not reported</td>
<td>22</td>
<td>22</td>
<td>Cases 16.9 Controls 17.0</td>
<td>Endothelin (means)</td>
</tr>
<tr>
<td>4. Barden 1999, Australia</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP+MP</td>
<td>Not reported</td>
<td>Not reported</td>
<td>62</td>
<td>84</td>
<td>0.5 (6months)</td>
<td>Endothelin (means)</td>
</tr>
<tr>
<td>5. He 1999, Sweden</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP+MP</td>
<td>Not reported</td>
<td>Not reported</td>
<td>24</td>
<td>23</td>
<td>Range:2-5</td>
<td>Fibrinogen, VWF, PAI-1, tPA (medians)</td>
</tr>
<tr>
<td>6. Chambers 2001*, England</td>
<td>Prospective CaseControl</td>
<td>PE</td>
<td>NP+MP</td>
<td>Not reported</td>
<td>Not reported</td>
<td>78</td>
<td>48</td>
<td>Mean:3</td>
<td>Homocysteine, E-selectin, ICAM (means)</td>
</tr>
<tr>
<td>7. Sattar 2003, Scotland</td>
<td>Retrospective Cohort</td>
<td>PE</td>
<td>NP</td>
<td>Cases 36 Controls 40</td>
<td>PT+T</td>
<td>40</td>
<td>40</td>
<td>Range:18-28</td>
<td>ICAM, VCAM, E-selectin (medians)</td>
</tr>
<tr>
<td>8. Vickers 2003*, Scotland</td>
<td>Prospective Cohort</td>
<td>PE+PIH</td>
<td>NP</td>
<td>Not reported</td>
<td>Not reported</td>
<td>392+297</td>
<td>163</td>
<td>Range:33-52</td>
<td>Fibrinogen, VWF (means)</td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
<td>Design</td>
<td>Group 1</td>
<td>Group 2</td>
<td>Case Numbers</td>
<td>Follow-up</td>
<td>Outcome Measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
<td>--------</td>
<td>---------</td>
<td>---------</td>
<td>--------------</td>
<td>-----------</td>
<td>------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Freeman 2004*, Scotland</td>
<td>2004*</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP</td>
<td>Not reported</td>
<td>40</td>
<td>Mean: 19.8 (cases), 19.9 (controls)</td>
<td>ICAM, VCAM, IL-6, IL-10, TNF-α (means)</td>
<td></td>
</tr>
<tr>
<td>Raijmakers 2004*, Netherlands</td>
<td>2004*</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP+MP</td>
<td>Not reported</td>
<td>113</td>
<td>2 (28months)</td>
<td>Homocysteine (means)</td>
<td></td>
</tr>
<tr>
<td>Wolff 2004, USA</td>
<td>2004</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP</td>
<td>Not reported</td>
<td>29</td>
<td>2 (18±7.9 months)</td>
<td>sFt-1 (means), VEGF (medians)</td>
<td></td>
</tr>
<tr>
<td>Paradisi 2006*, Italy</td>
<td>2006*</td>
<td>Prospective Cohort</td>
<td>PE+PIH</td>
<td>NP+MP</td>
<td>Cases 37.9 Controls 39.2</td>
<td>T</td>
<td>15</td>
<td>15 &gt;1 (20months)</td>
<td>Homocysteine (means)</td>
</tr>
<tr>
<td>Girourd 2007*, Canada</td>
<td>2007*</td>
<td>Prospective Cohort</td>
<td>PE+PIH</td>
<td>NP+MP</td>
<td>Cases 37.9 Controls 39.2</td>
<td>T</td>
<td>168</td>
<td>168 Mean: 7.8</td>
<td>Homocysteine (means)</td>
</tr>
<tr>
<td>Hamad 2007*, Sweden</td>
<td>2007*</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP</td>
<td>Not reported</td>
<td>18</td>
<td>1 (15months)</td>
<td>Fibrinogen, VWF, tPA, ICAM, VCAM, E-selectin (means)</td>
<td></td>
</tr>
<tr>
<td>v Rijn 2007*, Netherlands</td>
<td>2007*</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP</td>
<td>Cases 29.9 Controls 40.0</td>
<td>PT+T</td>
<td>340</td>
<td>0.5 (&gt;6months)</td>
<td>Fibrinogen, IL-6, ICAM, VWF (means)</td>
</tr>
<tr>
<td>Lampinen 2008, Finland</td>
<td>2008</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP+MP</td>
<td>Cases 33 Controls 40</td>
<td>PT+T</td>
<td>28</td>
<td>20 Range:5-6</td>
<td>IL-6, VWF (medians)</td>
</tr>
</tbody>
</table>
Table 1. Continued

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Year, Country</th>
<th>Study Design</th>
<th>PE</th>
<th>Control</th>
<th>Cases</th>
<th>Controls</th>
<th>PT + T</th>
<th>Mean/ Median</th>
<th>Markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>17. Portelinha 2008, Portugal</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>Not reported</td>
<td>Cases 35 Controls 39</td>
<td>PT + T</td>
<td>65</td>
<td>54</td>
<td>Mean: 6</td>
<td>PAI-1 (means) Ddimer, Fibrinogen, tPA (medians)</td>
</tr>
<tr>
<td>18. Portelinha 2008*, Portugal</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP</td>
<td>Cases 34 Controls 39</td>
<td>PT + T</td>
<td>58</td>
<td>49</td>
<td>Mean: 6</td>
<td>VCAM, ICAM (means)</td>
</tr>
<tr>
<td>19. Coffeng 2011*, Netherlands</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP+MP</td>
<td>Not reported Not reported</td>
<td>16</td>
<td>17</td>
<td>Median: 4</td>
<td>Homocysteine (means)</td>
<td></td>
</tr>
<tr>
<td>20. Stepan 2011, Germany</td>
<td>Prospective Cohort</td>
<td>PE</td>
<td>Not reported</td>
<td>Not reported Not reported</td>
<td>37</td>
<td>37</td>
<td>0.5 (6months)</td>
<td>TNFα (medians)</td>
<td></td>
</tr>
<tr>
<td>21. Gaugler 2012, Netherlands</td>
<td>Retrospective CaseControl</td>
<td>PE</td>
<td>NP+MP</td>
<td>Cases 22.8 Controls 40.2</td>
<td>PT + T</td>
<td>16</td>
<td>18</td>
<td>Median: 9.4 (cases) 9.7 (controls)</td>
<td>sFlt, VEGF, E-selectin (medians)</td>
</tr>
</tbody>
</table>

*Studies included in meta-analyses
REFERENCES


